Henry Schein Inc., a leading provider of healthcare products and services, reported its fourth quarter and full year 2024 financial results. It highlighted strong global sales growth despite missing some analyst estimates. The company also provided detailed financial guidance for 2025. Major executive stock sales were noted, with CEO Bradford Connett selling $287,161 in stock. However, the company's 14-year ethical leadership streak and social impact were underlined, with Ethisphere naming it one of the 2025 World's Most Ethical Companies.
The firm announced a strategic investment by KKR and related board changes, which analysts believe will provide a significant boost. The company also completed its acquisition of Acentus, boosting its homecare medical product offerings. Concerns, however, were raised around HSIC's returns on capital. Amidst these developments, HSIC appears to have an overall bullish outlook according to technical analysis, although some cite reasons to sell the stock.
Henry Schein HSIC News Analytics from Wed, 10 Jul 2024 07:00:00 GMT to Fri, 21 Mar 2025 23:29:08 GMT - Rating 2 - Innovation 5 - Information 8 - Rumor -1
